By InvitationNot Applicable

Intraocular Gas Tamponade for Treatment of Large Idiopathic Macular Holes

Ukraine100 participantsStarted 2025-02-01

Plain-language summary

The goal of this clinical trial is to evaluate the visual and anatomical outcomes of large (410-1000 μm) full-thickness macular holes repair surgery using perfluoropropane (15% C3F8), sulfur hexafluoride (20% SF6) gas tamponade.

Who can participate

Age range50 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient age 50 or above. * Duration of Symptoms ≤ 12 months. * Macular holes having a diameter 410-1000 μm. * Informed consent. Exclusion Criteria: * Patients under 50 years of age. * A patient who has already undergone treatment (surgery, laser etc.) for any disease of the retina. * Traumatic or pediatric macular holes, and associated retinal detachment. * History of any retinal disease such as high myopia, retinal dystrophies, central serous retinopathy, retinal vascular diseases, diabetic retinopathy, uveitis etc. * Previous history of glaucoma or ocular hypertension. * Failure to give informed consent.

What they're measuring

Closure of macular holes

Timeframe: 6 months

Type of macular hole closure

Timeframe: 6 months

Trial details

NCT IDNCT06927544

SponsorThe Filatov Institute of Eye Diseases and Tissue Therapy

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-02-01

View on ClinicalTrials.gov More Idiopathic Macular Hole trials